35075109|t|Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
35075109|a|Multiple myeloma (MM) patients typically receive several lines of combination therapy and first-line treatment commonly includes lenalidomide. As patients age, they become less tolerant to treatment, requiring convenient/tolerable/lenalidomide-free options. Carfilzomib and/or bortezomib-exposed/intolerant, lenalidomide-refractory MM patients with >=2 prior lines of therapy were randomized 3:2 to ixazomib-dexamethasone (ixa-dex) (n = 73) or pomalidomide-dexamethasone (pom-dex) (n = 49) until progression/toxicity. Median progression-free survival (mPFS) was 7.1 vs 4.8 months with ixa-dex vs pom-dex (HR 0.847, 95% CI 0.535-1.341, P = 0.477; median follow-up: 15.3 vs 17.3 months); there was no statistically significant difference between arms. In patients with 2 and >=3 prior lines of therapy, respectively, mPFS was 11.0 vs 5.7 months (HR 1.083, 95% CI 0.547-2.144) and 5.7 vs 3.7 months (HR 0.686, 95% CI 0.368-1.279). Among ixa-dex vs pom-dex patients, 69% vs 81% had Grade >=3 treatment-emergent adverse events (TEAEs), 51% vs 53% had serious TEAEs, 39% vs 36% had TEAEs leading to drug discontinuation, 44% vs 32% had TEAEs leading to dose reduction, and 13% vs 13% died on study. Quality of life was similar between arms and maintained during treatment. Ixa-dex represents an important lenalidomide-free, oral option for this heavily pretreated, lenalidomide-refractory, proteasome inhibitor-exposed population.Trial registration: ClinicalTrials.gov number, NCT03170882.
35075109	5	13	ixazomib	Chemical	MESH:C548400
35075109	14	27	dexamethasone	Chemical	MESH:D003907
35075109	36	48	pomalidomide	Chemical	MESH:C467566
35075109	49	62	dexamethasone	Chemical	MESH:D003907
35075109	67	79	lenalidomide	Chemical	MESH:D000077269
35075109	121	137	multiple myeloma	Disease	MESH:D009101
35075109	167	183	Multiple myeloma	Disease	MESH:D009101
35075109	185	187	MM	Disease	MESH:D009101
35075109	189	197	patients	Species	9606
35075109	296	308	lenalidomide	Chemical	MESH:D000077269
35075109	313	321	patients	Species	9606
35075109	398	410	lenalidomide	Chemical	MESH:D000077269
35075109	425	436	Carfilzomib	Chemical	MESH:C524865
35075109	444	454	bortezomib	Chemical	MESH:D000069286
35075109	475	487	lenalidomide	Chemical	MESH:D000077269
35075109	499	501	MM	Disease	MESH:D009101
35075109	502	510	patients	Species	9606
35075109	566	574	ixazomib	Chemical	MESH:C548400
35075109	575	588	dexamethasone	Chemical	MESH:D003907
35075109	590	594	ixa-	Chemical	-
35075109	594	597	dex	Chemical	MESH:D003915
35075109	611	623	pomalidomide	Chemical	MESH:C467566
35075109	624	637	dexamethasone	Chemical	MESH:D003907
35075109	639	642	pom	Chemical	-
35075109	643	646	dex	Chemical	MESH:D003915
35075109	675	683	toxicity	Disease	MESH:D064420
35075109	752	755	ixa	Chemical	-
35075109	756	759	dex	Chemical	MESH:D003915
35075109	763	766	pom	Chemical	-
35075109	767	770	dex	Chemical	MESH:D003915
35075109	920	928	patients	Species	9606
35075109	1101	1104	ixa	Chemical	-
35075109	1105	1108	dex	Chemical	MESH:D003915
35075109	1112	1115	pom	Chemical	-
35075109	1116	1119	dex	Chemical	MESH:D003915
35075109	1120	1128	patients	Species	9606
35075109	1165	1188	emergent adverse events	Disease	MESH:D064420
35075109	1190	1195	TEAEs	Disease	MESH:D064420
35075109	1221	1226	TEAEs	Disease	MESH:D064420
35075109	1243	1248	TEAEs	Disease	MESH:D064420
35075109	1297	1302	TEAEs	Disease	MESH:D064420
35075109	1345	1349	died	Disease	MESH:D003643
35075109	1434	1437	Ixa	Chemical	-
35075109	1438	1441	dex	Chemical	MESH:D003915
35075109	1466	1478	lenalidomide	Chemical	MESH:D000077269
35075109	1526	1538	lenalidomide	Chemical	MESH:D000077269
35075109	Cotreatment	MESH:C548400	MESH:D003907
35075109	Negative_Correlation	MESH:D000069286	MESH:D009101
35075109	Cotreatment	MESH:D003907	MESH:D003915
35075109	Negative_Correlation	MESH:D000077269	MESH:D009101
35075109	Negative_Correlation	MESH:C467566	MESH:D009101
35075109	Positive_Correlation	MESH:D003915	MESH:D064420
35075109	Negative_Correlation	MESH:C548400	MESH:D009101
35075109	Cotreatment	MESH:C467566	MESH:D003907
35075109	Cotreatment	MESH:D000069286	MESH:D000077269
35075109	Negative_Correlation	MESH:D003907	MESH:D009101
35075109	Negative_Correlation	MESH:D003915	MESH:D009101
35075109	Negative_Correlation	MESH:C524865	MESH:D009101
35075109	Comparison	MESH:C467566	MESH:C548400
35075109	Cotreatment	MESH:C548400	MESH:D003915

